Characteristics of Office-Based Buprenorphine Prescribers for Medicare Patients

References

1. 1.↵
   Centers for Disease Control and Prevention. Understanding the epidemic. Available from: https://www.cdc.gov/drugoverdose/epidemic/index.html. Published 2018. Accessed June 23, 2019.
2. 2.↵
   Pew Charitable Trusts. The case for medication-assisted treatment, 2017. Available from: https://www.pewtrusts.org/en/research-and-analysis/fact-sheets/2017/02/the-case-for-medication-assisted-treatment. Published 2017. Accessed on June, 23, 2019.
3. 3.↵
   1. Tsui JI,
   2. Evans JL,
   3. Lum PJ,
   4. Hahn JA,
   5. Page K

   . Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med 2014;174:1974–81.

   OpenUrl
4. 4.↵
   1. French MT,
   2. Zarkin GA,
   3. Hubbard RL,
   4. Rachal JV

   . The effects of time in drug abuse treatment and employment on posttreatment drug use and criminal activity. Am J Drug Alcohol Abuse 1993;19:19–33.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Merrill J,
   2. Alterman A,
   3. Cacciola J,
   4. Rutherford M

   . Prior treatment history and its impact on criminal recidivism. J Subst Abuse Treat 1999;17:313–9.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Rinaldo SG,
   2. Rinaldo DW

   . Availability without accessibility? State Medicaid coverage and authorization requirements for opioid dependence medications. In: Advancing Access to Addiction Medications: Implications for Opioid Addiction Treatment. Rockville, MD: American Society of Addition Medicine; 2013. P. 9–71.
7. 7.↵
   1. Dick AW,
   2. Pacula RL,
   3. Gordon AJ,
   4. et al

   . Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002–11. Health Aff (Millwood) 2015;34:1028–34.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   Substance Abuse and Mental Health Services Administration. Practitioner and Program Data. Available from: https://www.samhsa.gov/medication-assisted-treatment/training-materials-resources/practitioner-program-data. Published 2019. Accessed on December, 10, 2019.
9. 9.↵
   1. Stein BD,
   2. Dick AW,
   3. Sorbero M,
   4. et al

   . A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees. Subst Abus 2018;39:419–25.

   OpenUrl
10. 10.↵
    1. D'Onofrio G,
    2. O'Connor PG,
    3. Pantalon MV,
    4. et al

    . Emergency department–initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA 2015;313:1636–44.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Liebschutz JM,
    2. Crooks D,
    3. Herman D,
    4. et al

    . Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med 2014;174:1369–76.

    OpenUrl
12. 12.↵
    1. Wingrove P,
    2. Park B,
    3. Bazemore A

    . Rural opioid use disorder treatment depends on family physicians. Am Fam Physician, 2016;94:546.

    OpenUrl
13. 13.↵
    1. Crothers J,
    2. Petterson S,
    3. Bazemore A,
    4. Wingrove P

    . Family medicine: an underutilized resource in addressing the opioid epidemic. Am Fam Physician, 2016;94:350.

    OpenUrl
14. 14.↵
    1. Andrilla CA,
    2. Moore TE,
    3. Patterson DG

    . Overcoming barriers to prescribing buprenorphine for the treatment of opioid use disorder: recommendations from rural physicians. J Rural Health 2019;35:113–21.

    OpenUrl
15. 15.↵
    1. Lin LA,
    2. Knudsen HK

    . Comparing buprenorphine-prescribing physicians across nonmetropolitan and metropolitan areas in the United States. Ann Fam Med 2019;17:212–20.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Huhn AS,
    2. Dunn KE

    . Why aren't physicians prescribing more buprenorphine? J Subst Abuse Treat 2017;78, 1–7.

    OpenUrlPubMed
17. 17.↵
    1. Davenport S,
    2. Matthews K

    . Opioid use disorder in the United States: diagnosed prevalence by payer, age, sex, and state. Milliman White Paper. Available from: http://www.milliman.com/insight/2018/Opioid-use-disorder-in-the-United-States-Diagnosed-prevalence-by-payer–age–sex–and-state/. Published 2018. Accessed on June, 23, 2019.
18. 18.↵
    1. Tesema L,
    2. Marshall J,
    3. Hathaway R,
    4. Pham C,
    5. Clarke C,
    6. Bergeron G

    . Training in office-based opioid treatment with buprenorphine in US residency programs: a national survey of residency program directors. Subst Abus 2018;39:1–7.

    OpenUrl
19. 19.↵
    1. Wen H,
    2. Borders TF,
    3. Cummings JR

    . Trends in buprenorphine prescribing by physician specialty. Health Aff 2019;38:24–8.

    OpenUrl
20. 20.↵
    1. Parran TV,
    2. Muller JZ,
    3. Chernyak E,
    4. et al

    . Access to and payment for office-based buprenorphine treatment in Ohio. Subst Abus 2017;11,1–6.

    OpenUrl
21. 21.↵
    1. Cubanski D,
    2. Damico A,
    3. Neuman T

    . Medicare Part D in 2018: the latest on enrollment, premiums, and cost sharing. Kaiser Family Foundation. Available from: https://www.kff.org/medicare/issue-brief/medicare-part-d-in-2018-the-latest-on-enrollment-premiums-and-cost-sharing/. Published 2018. Accessed on September, 27, 2019.